ANK1 | Ankyrin 1, erythrocytic | Cytoskeleton related proteins Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ANKEF1 | Ankyrin repeat and EF-hand domain containing 1 | | | | | | Tissue enhanced |
ANKRD2 | Ankyrin repeat domain 2 (stretch responsive muscle) | | | | | | Group enriched |
ANKRD45 | Ankyrin repeat domain 45 | | | | | | Tissue enhanced |
ANKRD65 | Ankyrin repeat domain 65 | | | | | | Tissue enhanced |
ANLN | Anillin, actin binding protein | | | | | | Tissue enhanced |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ANO4 | Anoctamin 4 | Predicted membrane proteins
| | | | | Tissue enhanced |
ANPEP | Alanyl (membrane) aminopeptidase | CD markers Enzymes Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
ANXA10 | Annexin A10 | | | | | | Tissue enriched |
ANXA13 | Annexin A13 | Plasma proteins
| | | | | Tissue enhanced |
AOC1 | Amine oxidase, copper containing 1 | Enzymes Predicted secreted proteins
| | | | | Group enriched |
AOC3 | Amine oxidase, copper containing 3 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AOX1 | Aldehyde oxidase 1 | Enzymes Plasma proteins
| | | | | Tissue enhanced |
AP3B2 | Adaptor-related protein complex 3, beta 2 subunit | | | | | | Tissue enhanced |
APBA1 | Amyloid beta (A4) precursor protein-binding, family A, member 1 | | | | | | Tissue enhanced |
APCS | Amyloid P component, serum | Disease related genes Plasma proteins Potential drug targets Predicted secreted proteins Transporters
| | | | | Tissue enriched |
APLP1 | Amyloid beta (A4) precursor-like protein 1 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
APOA1 | Apolipoprotein A-I | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
APOA4 | Apolipoprotein A-IV | Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
APOB | Apolipoprotein B | Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
APOBEC2 | Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 | | | | | | Group enriched |
APOC2 | Apolipoprotein C-II | Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
APOC4 | Apolipoprotein C-IV | Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
APOC4-APOC2 | APOC4-APOC2 readthrough (NMD candidate) | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
APOH | Apolipoprotein H (beta-2-glycoprotein I) | Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
APOM | Apolipoprotein M | Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
AQP12A | Aquaporin 12A | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
AQP12B | Aquaporin 12B | Predicted membrane proteins
| | | | | Tissue enriched |
AQP2 | Aquaporin 2 (collecting duct) | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
AQP3 | Aquaporin 3 (Gill blood group) | Blood group antigen proteins Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
AQP4 | Aquaporin 4 | Predicted membrane proteins Transporters
| | | | | Group enriched |
AQP5 | Aquaporin 5 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
AQP6 | Aquaporin 6, kidney specific | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
AQPEP | Aminopeptidase Q | Enzymes Predicted secreted proteins
| | | | | Group enriched |
AR | Androgen receptor | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Plasma proteins Transcription factors
| | | | | Tissue enhanced |
ARC | Activity-regulated cytoskeleton-associated protein | | | | | | Tissue enhanced |
ARG1 | Arginase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
ARG2 | Arginase 2 | Cancer-related genes Enzymes Mitochondrial proteins
| | | | | Group enriched |
ARHGAP25 | Rho GTPase activating protein 25 | Plasma proteins
| | | | | Tissue enhanced |
ARHGAP28 | Rho GTPase activating protein 28 | | | | | | Tissue enhanced |
ARHGAP6 | Rho GTPase activating protein 6 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ARHGDIG | Rho GDP dissociation inhibitor (GDI) gamma | | | | | | Tissue enhanced |
ARMC3 | Armadillo repeat containing 3 | | | | | | Group enriched |
ARPP21 | CAMP-regulated phosphoprotein, 21kDa | | | | | | Group enriched |
ARSF | Arylsulfatase F | Predicted membrane proteins
| | | | | Tissue enhanced |
ART3 | ADP-ribosyltransferase 3 | Enzymes Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
AS3MT | Arsenic (+3 oxidation state) methyltransferase | Enzymes
| | | | | Tissue enriched |
ASB9 | Ankyrin repeat and SOCS box containing 9 | | | | | | Tissue enhanced |
ASGR1 | Asialoglycoprotein receptor 1 | | | | | | Tissue enriched |